[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.83.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1987

Effects of Antidepressant Treatments on Platelet Tritiated Imipramine Binding in Major Depressive Disorder

Author Affiliations

From the Department of Clinical Pharmacology, Karolinska Institute and Huddinge Hospital, Huddinge (Drs Wägner, Bertilsson, and Montero); Department of Psychiatry, Karolinska Institute, Danderyd Hospital, Danderyd (Dr Åberg-Wistedt); and Department of Psychiatry and Psychology, Karolinska Institute, Karolinska Hospital, Stockholm (Drs Wagner, Åsberg, and Mårtensson), Sweden.

Arch Gen Psychiatry. 1987;44(10):870-877. doi:10.1001/archpsyc.1987.01800220032006
Abstract

• The effects of four antidepressant treatments on platelet tritiated imipramine binding have been studied in 51 hospitalized patients with severe major depressive disorder. There was an increase in maximum binding (Bmax) during the first week of treatment with antidepressants and electroconvulsive therapy, which was further magnified after three weeks' treatment with the serotonin uptake blockers alaproclate and zimeldine hydrochloride, but the Bmax values returned to baseline levels with nortriptyline hydrochloride and electroconvulsive therapy. The equilibrium dissociation affinity constant (Kd) did not change with any of the treatments. On reexamination one or two years after admission to the study, Bmax had not reached control values in clinically recovered, drug-free patients. Low pretreatment Bmax was associated with delusions during illness and with a poor long-term clinical outcome. There was no correlation between binding parameters and monoamine metabolite concentrations in the cerebrospinal fluid, either before or during treatment.

×